Compare AbbVie Inc (ABBV) vs Wells Fargo & Co (WFC) Price & Performance

AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).

Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.

Wells Fargo (WFC) trades at $87.21, up 1.99% on the day, with a bullish technical signal from moving averages and oscillators. The stock shows solid fundamentals with a P/E of 13.52, net income margin of 25.53%, and ROE of 12.7%. Recent earnings have been mixed, with a beat in Q3 2025 but misses in Q4 2025 and Q1 2026. The company announced a dividend of $0.45 payable in June 2026, and Q2 2026 earnings are expected on July 14, 2026, with an EPS estimate of 1.73.

The outlook for WFC is cautiously optimistic, supported by analyst consensus with a $98.25 price target and 45% buy ratings. Key opportunities include potential earnings growth and dividend increases post-Fed stress tests. Risks involve volatile cash flows, regulatory changes impacting debit card fees, and competitive pressures in the banking sector. The stock's valuation remains attractive, but investors should monitor upcoming earnings for confirmation of growth trends.